Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/B3GALNT2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/B3GALNT2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/B3GALNT2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/B3GALNT2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00091002 | Esophagus | ESCC | glycoprotein metabolic process | 226/8552 | 387/18723 | 2.64e-07 | 3.94e-06 | 226 |
GO:00700854 | Esophagus | ESCC | glycosylation | 144/8552 | 240/18723 | 5.12e-06 | 5.38e-05 | 144 |
GO:00064865 | Esophagus | ESCC | protein glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
GO:00434135 | Esophagus | ESCC | macromolecule glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
GO:00091012 | Esophagus | ESCC | glycoprotein biosynthetic process | 181/8552 | 317/18723 | 2.54e-05 | 2.15e-04 | 181 |
GO:00064931 | Esophagus | ESCC | protein O-linked glycosylation | 51/8552 | 86/18723 | 7.54e-03 | 2.70e-02 | 51 |
GO:0006493 | Lung | AIS | protein O-linked glycosylation | 17/1849 | 86/18723 | 4.04e-03 | 3.65e-02 | 17 |
GO:00064863 | Lung | AIS | protein glycosylation | 35/1849 | 226/18723 | 4.93e-03 | 4.27e-02 | 35 |
GO:00434133 | Lung | AIS | macromolecule glycosylation | 35/1849 | 226/18723 | 4.93e-03 | 4.27e-02 | 35 |
GO:00064866 | Thyroid | PTC | protein glycosylation | 94/5968 | 226/18723 | 1.25e-03 | 7.13e-03 | 94 |
GO:00434136 | Thyroid | PTC | macromolecule glycosylation | 94/5968 | 226/18723 | 1.25e-03 | 7.13e-03 | 94 |
GO:00700855 | Thyroid | PTC | glycosylation | 96/5968 | 240/18723 | 4.57e-03 | 2.15e-02 | 96 |
GO:00091013 | Thyroid | PTC | glycoprotein biosynthetic process | 123/5968 | 317/18723 | 5.05e-03 | 2.33e-02 | 123 |
GO:00091003 | Thyroid | PTC | glycoprotein metabolic process | 147/5968 | 387/18723 | 5.87e-03 | 2.64e-02 | 147 |
GO:000648612 | Thyroid | ATC | protein glycosylation | 94/6293 | 226/18723 | 7.11e-03 | 2.82e-02 | 94 |
GO:004341312 | Thyroid | ATC | macromolecule glycosylation | 94/6293 | 226/18723 | 7.11e-03 | 2.82e-02 | 94 |
GO:000910011 | Thyroid | ATC | glycoprotein metabolic process | 153/6293 | 387/18723 | 7.90e-03 | 3.06e-02 | 153 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
B3GALNT2 | SNV | Missense_Mutation | novel | c.179N>T | p.Ala60Val | p.A60V | Q8NCR0 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-LL-A73Z-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
B3GALNT2 | insertion | Nonsense_Mutation | novel | c.778_779insAGAGAAAGAAAG | p.Leu260delinsTer | p.L260delins* | Q8NCR0 | protein_coding | | | TCGA-AR-A0U2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | PD |
B3GALNT2 | SNV | Missense_Mutation | rs747653180 | c.259C>T | p.Arg87Cys | p.R87C | Q8NCR0 | protein_coding | deleterious(0.01) | probably_damaging(0.98) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
B3GALNT2 | SNV | Missense_Mutation | | c.1479T>G | p.Asp493Glu | p.D493E | Q8NCR0 | protein_coding | deleterious(0.01) | benign(0.424) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
B3GALNT2 | SNV | Missense_Mutation | | c.148C>G | p.His50Asp | p.H50D | Q8NCR0 | protein_coding | deleterious(0.04) | benign(0.108) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
B3GALNT2 | deletion | Frame_Shift_Del | | c.1148delG | p.Gly383GlufsTer5 | p.G383Efs*5 | Q8NCR0 | protein_coding | | | TCGA-AA-3973-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Targeted Molecular therapy | bevacizumab | SD |
B3GALNT2 | SNV | Missense_Mutation | novel | c.973N>C | p.Val325Leu | p.V325L | Q8NCR0 | protein_coding | tolerated(0.05) | benign(0.015) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
B3GALNT2 | SNV | Missense_Mutation | rs377646173 | c.493N>A | p.Asp165Asn | p.D165N | Q8NCR0 | protein_coding | tolerated(0.25) | benign(0.003) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
B3GALNT2 | SNV | Missense_Mutation | novel | c.1076N>A | p.Cys359Tyr | p.C359Y | Q8NCR0 | protein_coding | deleterious(0.04) | possibly_damaging(0.586) | TCGA-A5-A2K3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD |
B3GALNT2 | SNV | Missense_Mutation | novel | c.256N>A | p.Gln86Lys | p.Q86K | Q8NCR0 | protein_coding | tolerated(0.32) | benign(0) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |